Baraclude
developed to manage chronic hepatitis b infection to alleviate viral replication.
Strengths: 0.5mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Hepatitis B Antiviral
- Pharmacological class
Nucleoside Analogue
- Contraindications
hypersensitivity to entecavir
- Minor side effects
headache; fatigue
- Moderate side effects
dizziness; nausea
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Bristol-Myers Squibb
- Onset Time
varies
- Duration
24 hours
- Storage instructions
Store below 25°C.
- Drug interactions
drugs affecting renal function
- Pregnancy and breastfeeding
Pregnancy: use only if clearly necessary. Breastfeeding: not recommended.
Precautions and warnings
risk of lactic acidosis; severe acute exacerbations of hepatitis upon discontinuation; monitor renal function
Serious side effects
lactic acidosis — requires immediate medical attention; severe hepatomegaly with steatosis — requires immediate medical attention
Patient summary
developed to manage chronic hepatitis b infection to alleviate viral replication.
Mechanism of action
Inhibits hepatitis B virus polymerase, which interferes with the viral replication process.
Baraclude
developed to manage chronic hepatitis b infection to alleviate viral replication.
Editorial Notes
- Active ingredient(s): Entecavir
- Listed indication(s): Chronic Hepatitis B
Available option
- 30 tablets - 0.5 mg1498-0-5-mg-17758